Severity of non‐alcoholic steatohepatitis is associated with substitution of adipose tissue in skeletal muscle
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Background and Aims: The pathogenesis of non‐alcoholic fatty liver disease (NAFLD) is now focusing on its organ cross‐talk with not only adipose tissue but also systemic skeletal muscle. Cross‐sectional and longitudinal studies were conducted to determine the role of intramuscular adipose tissue content (IMAC) measured by computed tomography on the severity of NAFLD/non‐alcoholic steatohepatitis (NASH). Methods: Two hundred eight J apanese patients with NAFLD/NASH diagnosed by liver biopsy were enrolled into a cross‐sectional study. Twenty‐one patients were enrolled in a longitudinal study and received a programmed diet and exercise intervention, in some cases the combination of pharmacotherapy. We measured IMAC in the multifidus muscle and biochemical parameters, and conducted liver histology to assess NAFLD/NASH status. Results: Histopathological stage in terms of simple steatosis and B runt's classification was significantly correlated with IMAC (P < 0.01). Multivariate logistic regression analysis indicated that risk factors associated with the severity of NASH were IMAC and aging (IMAC: odds ratio = 2.444, P < 0.05; Age: odds ratio = 2.355, P < 0.05). The interventions improved histopathological changes in 11 patients with NASH as well as IMAC. Conclusion: These results suggest that skeletal muscle fat accumulation may have been linked to the pathogenesis and severity of NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021
C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
Pradhan, A. D. (2001) · JAMA · doi:10.1001/jama.286.3.327 · Cited by 4,433
Abdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354
Katz, A., Nambi, S. S., Mather, K., Baron, A. D., Follmann, D. A., Sullivan, G., & Quon, M. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6661 · Cited by 3,931
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Muscle as an Endocrine Organ: Focus on Muscle-Derived Interleukin-6
Pedersen, B. K., & Febbraio, M. A. (2008) · Physiological Reviews · doi:10.1152/physrev.90100.2007 · Cited by 2,388
Relation of Body Fat Distribution to Metabolic Complications of Obesity*
KISSEBAH, A. H., VYDELINGUM, N., MURRAY, R., EVANS, D. J., KALKHOFF, R. K., & ADAMS, P. W. (1982) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-54-2-254 · Cited by 1,909
New Criteria for `Obesity Disease' in Japan
The Examination Committee of Criter (2002) · Circulation Journal · doi:10.1253/circj.66.987 · Cited by 1,650
Goodpaster, B. H., Leland Thaete, F., Simoneau, J.-A., & Kelley, D. E. (1997) · Diabetes · doi:10.2337/diacare.46.10.1579 · Cited by 1,012
Cited by
Okumura, S., Kaido, T., Hamaguchi, Y., Fujimoto, Y., Masui, T., Mizumoto, M., Hammad, A., Mori, A., Takaori, K., & Uemoto, S. (2015) · Surgery · doi:10.1016/j.surg.2015.02.002 · Cited by 271
Impact of quality as well as quantity of skeletal muscle on outcomes after liver transplantation
Hamaguchi, Y., Kaido, T., Okumura, S., Fujimoto, Y., Ogawa, K., Mori, A., Hammad, A., Tamai, Y., Inagaki, N., & Uemoto, S. (2014) · Liver Transplantation · doi:10.1002/lt.23970 · Cited by 242
Nachit, M., Kwanten, W. J., Thissen, J.-P., Op De Beeck, B., Van Gaal, L., Vonghia, L., Verrijken, A., Driessen, A., Horsmans, Y., Francque, S., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.02.037 · Cited by 114
Nachit, M., De Rudder, M., Thissen, J., Schakman, O., Bouzin, C., Horsmans, Y., Vande Velde, G., & Leclercq, I. A. (2021) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12646 · Cited by 82
“For instance, Kitajima et al.17 reported an association between myosteatosis and NASH severity in NAFLD patients (n = 208).”
BackgroundInteraction between sarcopenia and nonalcoholic fatty liver disease
Joo, S. K., & Kim, W. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0358 · Cited by 78
Chen, V. L., Wright, A. P., Halligan, B., Chen, Y., Du, X., Handelman, S. K., Long, M. T., Kiel, D. P., & Speliotes, E. K. (2019) · Hepatology Communications · doi:10.1002/hep4.1391 · Cited by 28
Osteosarcopenia in NAFLD/MAFLD: an underappreciated clinical problem in chronic liver disease
Musio, A., Perazza, F., Leoni, L., Stefanini, B., Dajti, E., Menozzi, R., Petroni, M. L., Colecchia, A., & Ravaioli, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087517 · Cited by 26
“It is associated with an increased prevalence of NAFLD [16], with the presence and severity of NASH [17] and significant fibrosis [18].”
BackgroundHaxhi, J., Vitale, M., Mattia, L., Giuliani, C., Sacchetti, M., Orlando, G., Iacobini, C., Menini, S., Zanuso, S., Nicolucci, A., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1393859 · Cited by 5
Metadata
- Authors
- Kitajima, Y., Hyogo, H., Sumida, Y., Eguchi, Y., Ono, N., Kuwashiro, T., Tanaka, K., Takahashi, H., Mizuta, T., Ozaki, I., Eguchi, T., Kimura, Y., Fujimoto, K., Anzai, K., & Japan Nonalcoholic Fatty Liver Disease Study Group (JSG‐NAFLD)
- Venue
- Journal of Gastroenterology and Hepatology
- Publisher
- Wiley
- Published
- 2013-08-22
- Volume
- 28
- Issue
- 9
- Pages
- 1507-1514
- ISSN
- 0815-9319 (ISSN-L)
- 1440-1746
- OpenAlex
- W1597545563
- Cited by
- 131
- References
- 16
- FWCI
- 4.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.